Tolvaptan efficacy and safety in management of polycystic kidney desease and its outcomes (TEMPO3/4) Tolvaptan efficacy and safety in management of polycystic kidney desease and its outcomes (TEMPO3/4) ...
A phase 3, multi-center, double-blind, placebo-controlled, parallel-arm trial to determine long-term safety and efficacy of oral tolvaptan regimens in adult subjects with autosomal dominant polycystic kidney disease (ADPKD) A phase 3, multi-center, double-blind, placebo-controlled, parallel-arm trial to determine long-term ...
Intervention name : OPC-41061 (tolvaptan) INN of the intervention : Tolvaptan Dosage And administration of the intervention : Oral, 45/15 mg Intervention name : OPC-41061 (tolvaptan) INN of the intervention : Tolvaptan Dosage And administration of the intervention : Oral, 60/30 mg Intervention name : OPC-41061 (tolvaptan) INN of the intervention : Tolvaptan Dosage And administration of the intervention : Oral, 90/30 mg Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Oral Intervention name : OPC-41061 (tolvaptan) INN of the intervention : Tolvaptan Dosage And administratio ...
Otsuka Pharmaceutical Co., Ltd.
NULL
complete
20
50
BOTH
1500
Phase 3
Japan, North America, South America, Europe, Oceania